INCYTE (ICY BE) stock market data APIs
€80.2586
0.93(1.2%)
as of December 12, 2025
Try our APIs with
free plan!
INCYTE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ICY.BE.
Prev. Close
80.2586
Open
81.1841
High
81.2633
Low
79.8682
52 wk Range
48.23-94.46
Market Cap
12 792 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INCYTE data using free add-ons & libraries
Get INCYTE Fundamental Data
INCYTE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INCYTE News
New
Incyte Announces Change to its Board of Directors
WILMINGTON, Del., December 12, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company’s Board of Directors, effective immediately. As previou...
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap?
If you are wondering whether Incyte at around $96.70 is still a smart buy after its big run, you are in the right place to dig into what the market might be getting right or wrong about its value. Des...
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower?
Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential thrombo...
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at the higher dose achieved a hematologic response (HR) with 83.3% achieving a complete HR Molecular responses were...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
